Form 8-K - Current report:
SEC Accession No. 0000950170-24-123255
Filing Date
2024-11-07
Accepted
2024-11-07 16:03:32
Documents
13
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnth-20241107.htm   iXBRL 8-K 44533
2 EX-99.1 dnth-ex99_1.htm EX-99.1 244275
3 GRAPHIC img85518887_0.jpg GRAPHIC 4257
  Complete submission text file 0000950170-24-123255.txt   465457

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dnth-20241107.xsd EX-101.SCH 57693
15 EXTRACTED XBRL INSTANCE DOCUMENT dnth-20241107_htm.xml XML 4698
Mailing Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Dianthus Therapeutics, Inc. /DE/ (Filer) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38541 | Film No.: 241435445
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)